In the wake of an Ebola outbreak in West Africa that has resulted in nearly 900 deaths, a tiny pharmaceutical maker has allowed an experimental treatment to be used for two Americans infected with the deadly virus.

西非地区爆发的埃博拉病毒已经导致近900人死亡，现在，一家小型制药公司研制出了一款试验性药物，该药物已经用于治疗两名被感染的美国人。

California-based Mapp Biopharmaceutical has released its experimental ZMapp drug, which had only been tested on infected animals, to treat Kent Brantly and Nancy Writebol, according to Bloomberg News. The two health workers were infected while working in Liberia. The treatments for now appear to be working, Bloomberg said, citing relatives and supporters.

据彭博社报道，总部位于加利福尼亚州的Mapp生物制药公司最近推出了一款名叫ZMapp的试验性药物，该药之前只在感染了埃博拉病毒的动物身上测试过，现在正用于治疗肯特o布兰特利和南茜o莱特博尔，这两位医务人员在利比里亚工作期间感染了埃博拉病毒。据彭博社（Bloomberg News）从病人家属和看护人员那里了解到的情况看，目前这种药物已经起效了。

Here are five things to know about Mapp and its efforts to develop a potential treatment for the Ebola virus.

关于Mapp生物制药公司，以及它推出的这款抗埃博拉病毒药物，有五点值得我们了解。

【人类需要了解的有关抗埃博拉病毒药物的五件事】相关文章：

★ 无聊程度测试题：快来算算你是不是很无聊！

★ 如何正确清洁牙齿

★ 皮特低调参加前妻生日派对？这是要闹哪样

★ BEC商务英语初级写作必备黄金句(2)

★ 我国科学家发现了可抑制HIV扩散的蛋白质

★ 全球首款治疗产后抑郁的新药问世了

★ 法国致命麻醉师：为了炫技投毒致9人死亡

★ 环境摄影大师韶华用影像诉说环保：消失的扬子鳄

★ 比伯婚礼或将在3月举办？

★ 避孕药或有助于降低患卵巢癌的风险